Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 233

Sort by

Sort Order Select

Journal Articles

PATCH trial: explanatory analyses

M. Irem Baharoglu, Rustam Al-Shahi Salman, Charlotte Cordonnier, Maria M. Koopman, Lynn Manson, Sophie Susen, Henk A. Marquering, Ludo F. Beenen, Charles B. Majoie, Yvo B. Roos

Blood (2020) 135 (16): 1406–1409.

https://doi.org/10.1182/blood.2019003298

Published: 2020

Includes: Supplemental data

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 668.

https://doi.org/10.1182/blood-2019-129288

Published: 2019

Journal Articles

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Blood (2019) 134 (Supplement_1): 1669.

https://doi.org/10.1182/blood-2019-131778

Published: 2019

Journal Articles

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Congli Zhang, Xin-xin Cao, Dong-zhu Li, Jun Feng, MD, Lu Zhang, MD, Yan Zhang, Ming-hui Duan, MD, Miao Chen, MD, Chen Yang, Wei Wang, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 2127.

https://doi.org/10.1182/blood-2019-125505

Published: 2019

Journal Articles

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

Dave Nellesen, PhD, Sedge Lucas, BA, Che-Rung Liu, MA., Menaka Bhor, PhD, Jincy Paulose, MD, Arthur Burnett, MD MBA

Blood (2019) 134 (Supplement_1): 3467.

https://doi.org/10.1182/blood-2019-128951

Published: 2019

Journal Articles

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Herve Ghesquieres, MD PhD, Olivier Casasnovas, MD, Emmanuelle Nicolas-Virelizier, MD, Damaj Gandhi Laurent, MD PhD, Vincent Delwail, MD, Mohamed Touati, MD, Katell Le Du, MD, Franck Morschhauser, MD PhD, Christophe Bonnet, MD, Agathe Waultier-Rascalou, MD, Frederique Orsini-Piocelle, MD, Marc André, Myriam Ben Boutieb, Fabienne Morand, Diane Damotte, MD PhD, Alexandra Traverse-Glehen, MD PhD, Philippe Quittet, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 2832.

https://doi.org/10.1182/blood-2019-129016

Published: 2019

Journal Articles

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Siavash Piran, MDMSc,FRCPC, Michelle Zondag, BSN, RN, Drew Bednar, MD FRCSC, Brian Drew, MD FRCSC, Agnes Chmiel, MD FRCPC, Noel Chan, MBBS, MRCP, FRACP, FRCPA, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Sam Schulman, MD PhD FRCPC

Blood (2019) 134 (Supplement_1): 2434.

https://doi.org/10.1182/blood-2019-124601

Published: 2019

Journal Articles

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Paul F Lindholm, MD, Hau C. Kwaan, MD PhD, Andrew M Naidech, MDMSPH

Blood (2019) 134 (Supplement_1): 4886.

https://doi.org/10.1182/blood-2019-128370

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

Alona A. Merkulova, MA, Steven C. Mitchell, MA, Sergei Merkulov, PhD, Alisa S. Wolberg, PhD, Neerman-Arbez Marguerite, PhD, Alvin H. Schmaier, MD

Blood (2019) 134 (Supplement_1): 4934.

https://doi.org/10.1182/blood-2019-131319

Published: 2019

Journal Articles

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

German Alejandro Detarsio, Sr., BSc, Mariana Raviola, Mauro Davoli, MD, Maria Fabiana Garcia

Blood (2019) 134 (Supplement_1): 4936.

https://doi.org/10.1182/blood-2019-125977

Published: 2019

Journal Articles

Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters

Carmelo Gurnari, MD, Francesca Di Giuliano, Mariadomenica Divona, Alfonso Piciocchi, Laura Cicconi, Adriano Venditti, Maria Ilaria Del Principe, William Arcese, Francesco Lo-Coco, Francesco Garaci, MD, Maria Teresa Voso, MD

Blood (2019) 134 (Supplement_1): 5170.

https://doi.org/10.1182/blood-2019-125058

Published: 2019

Journal Articles

Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study

Miguel A. Escobar, MD, Linda Shaffer, Mark Holguin, MD, Timothy McCavit, MD, Sandeep K. Rajan, MD, Novinyo Amega, MD

Blood (2019) 134 (Supplement_1): 4923.

https://doi.org/10.1182/blood-2019-122949

Published: 2019

Journal Articles

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Emilie Saucier, Florence Rabian, MD, Hélène Boutroux, MD, Marion Strullu, MD, Karine Morand, MD, Florian Chevillon, MD, Benoit Brethon, MD, Nicolas Boissel, MD PhD, Guy Leverger, MD, André Baruchel, MD

Blood (2019) 134 (Supplement_1): 5130.

https://doi.org/10.1182/blood-2019-131062

Published: 2019

Journal Articles

Study on the Possibility of Emergency Percutaneous Coronary Intervention (PCI) in Myeloproliferative Neoplasms (MPNs) Patients with Acute Coronary Syndrome (ACS)

Ye Chen, Xiuchuan Qin, Xue Han, Beibei Bai, Yingchun Wang

Blood (2019) 134 (Supplement_1): 5375.

https://doi.org/10.1182/blood-2019-124612

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

Safety Profile of Bone Marrow Aspiration and Biopsies Performed By the Hospitalist Procedure Service at an Academic Center: An Observational Study

Jennifer U Obasi, MD, Adrian P Umpierrez De Reguero, MD

Blood (2019) 134 (Supplement_1): 5848.

https://doi.org/10.1182/blood-2019-121444

Published: 2019

NARROW

PATCH trial: explanatory analyses

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Real World Data on Obstetric (OC) and Maternal Complications (MC) Occurring in a Cohort of Patients with Ph Negative Myeloproliferative Neoplasms (MPN): Argentinian Multicentric Study

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters

Immune Tolerance Induction (ITI) with a Plasma-Derived Factor VIII for Patients with Hemophilia a and Inhibitors: A Retrospective Study

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Study on the Possibility of Emergency Percutaneous Coronary Intervention (PCI) in Myeloproliferative Neoplasms (MPNs) Patients with Acute Coronary Syndrome (ACS)

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Safety Profile of Bone Marrow Aspiration and Biopsies Performed By the Hospitalist Procedure Service at an Academic Center: An Observational Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only